Dehradun-based medtech startup Sunfox Technologies has secured $7 million in a Series A round led by Ashish Kacholia and 3one4 Capital. The funds will support the expansion of its Spandan portable ECG platform and entry into US and European markets. Investors should note that the company is a private entity and is not available for retail trading.
Dehradun-based medical technology company Sunfox Technologies has raised $7 million in a Series A funding round. This financing was led by prominent investor Ashish Kacholia, along with Lashit Sanghvi, Alchemy Capital, and 3one4 Capital. The capital infusion marks the largest external investment for the startup since its inception in 2016, providing a significant boost to its growth initiatives.
The company is recognized for its Spandan portable ECG platform, which is designed to make heart diagnostics more accessible in remote areas. Currently, the platform has been deployed in 60,000 locations across 20,000 villages in India and processes approximately five million screenings annually. The operating model utilizes a hub-and-spoke system, allowing community health workers to record ECG data locally, which is then reviewed by cardiologists at district-level medical centers.
Sunfox intends to use these new funds to strengthen its research and development efforts. A primary objective is to accelerate the company’s footprint within India while preparing for international expansion. The startup has already secured regulatory approvals in several African markets, including Kenya, Ghana, Tanzania, and South Africa. Management is now navigating the complex regulatory pathways required for entry into the United States and the European Union, which will require building additional commercial and engineering infrastructure.
For investors tracking this space, it is important to understand that Sunfox Technologies is a private limited company and is currently not listed on any public stock exchange. This means that shares are not available for purchase through standard stock trading platforms. From a business perspective, the company faces execution risks as it scales, particularly regarding the development of the clinical evidence required for international regulatory compliance. Operating in the medtech sector also brings exposure to intense competition and strict oversight, as the company works to gain approvals in new, highly regulated markets. Future performance will depend on the company's ability to maintain its growth trajectory in India while overcoming the challenges of international market entry.